Expert consensus on diagnosis and clinical management of medication-related osteonecrosis of the jaw

doi:10.19438/j.cjoms.2023.04.001

China Journal of Oral and Maxillofacial Surgery ›› 2023, Vol. 21 ›› Issue (4): 313-325.doi: 10.19438/j.cjoms.2023.04.001

• Expert Consensus • Previous Articles Next Articles

Expert consensus on diagnosis and clinical management of medication-related osteonecrosis of the jaw

HE Yue¹, CHEN Heng¹, AN Jin-gang², GUO Yu-xing², PAN Jian³, TIAN Lei⁴, LIU Bing⁵, HOU Jin-song⁶, LI Jin-song⁷, JIANG Can-hua⁸, LI Meng-yu⁹, TIAN Zhen¹⁰, XU Jie¹¹, ZHU Ling¹², SUN Chang-fu¹³, ZHI Ke-qian¹⁴, QU Qing¹⁵, ZONG Chun-lin⁴, SUN Jing-jing¹⁰, ZHANG Zhi-yuan¹

1. Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology; Shanghai Research Institute of Stomatology. Shanghai 200011;
2. Department of Oral and Maxillofacial Surgery, Peking University Hospital of Stomatology. Beijing 100081;
3. Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology. Chengdu 610041, Sichuan Province;
4. Department of Oral and Maxillofacial Surgery, School of Stomatology, Air Force Military Medical University. Xi'an 710032, Shaanxi Province;
5. Department of Oral and Maxillofacial Surgery, Hospital of Stomatology, Wuhan University. Wuhan 430070, Hubei Province;
6. Department of Oral and Maxillofacial Surgery, Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University. Guangzhou 510055, Guangdong Province;
7. Department of Oral and Maxillofacial Surgery, Sun Yai-sen Memorial Hospital, Sun Yat-sen University. Guangzhou 510120, Guangdong Province;
8. Department of Oral and Maxillofacial Surgery, Xiangya Hospital,Central South University. Changsha 410078, Hunan Province;
9. Department of Oral and Maxillofacial Surgery, Hospital of Stomatology, Fudan University. Shanghai 200031;
10. Department of Oral Pathology, 11. Department of Infection, 12. Department of Imaging, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine. Shanghai 200011;
13. Department of Oromaxillofacial Head and Neck Surgery, School and Hospital of Stomatology, China Medical University. Shenyang 110001, Liaoning Province;
14. Department of Oral and Maxillofacial Repair and Reconstruction, Affiliated Hospital of Qingdao University. Qingdao 266003, Shandong Province;
15. Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Shanghai 200127, China

Received:2023-03-28 Revised:2023-04-20 Online:2023-07-20 Published:2023-08-16

Abstract

Abstract: Medication-related osteonecrosis of the jaw(MRONJ) is a complication caused by the application of anti-resorptive medications, angiogenesis inhibitors, hormones and other medications for the treatment of some systemic diseases. The clinical symptoms include swelling, pain, masticatory disorders, persistent fistula, bone exposure and even pathological fracture, which seriously affect the patients' quality of life. Domestically, there is a lack of consensus or guidelines on classification, staging and treatment of MRONJ, and different institutions make diagnosis and treatment plans empirically. In order to unify and standardize the diagnosis and treatment of MRONJ and improve the prognosis, an expert panel of MRONJ research from 12 famous domestic medical colleges and affiliated hospitals convened a meeting to discuss the diagnosis and treatment opinions of MRONJ. Meanwhile, consensus recommendations were also revised with a comprehensive literature review of the previous treatment experiences and research findings. Finally, this expert consensus was finished for clinical references.

Key words: Medication-related osteonecrosis of the jaw, Treatment guideline, Expert consensus

CLC Number:

R782

HE Yue, CHEN Heng, AN Jin-gang, GUO Yu-xing, PAN Jian, TIAN Lei, LIU Bing, HOU Jin-song, LI Jin-song, JIANG Can-hua, LI Meng-yu, TIAN Zhen, XU Jie, ZHU Ling, SUN Chang-fu, ZHI Ke-qian, QU Qing, ZONG Chun-lin, SUN Jing-jing, ZHANG Zhi-yuan. Expert consensus on diagnosis and clinical management of medication-related osteonecrosis of the jaw[J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(4): 313-325.

References

[1] Tenore G, Mohsen A, Rossi AF, et al.Does medication-related osteonecrosis of the jaw influence the quality of life of cancer patients?[J]. Biomedicines, 2020, 8(4): 95-105.
[2] 姜钧健, 何悦. 药物相关性颌骨坏死治疗方法的研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(5): 474-477.
Jiang JJ, He Y.Research progress on treatment of medication-related osteonecrosis of the jaw[J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(5): 474-477.
[3] Yarom N, Shapiro CL, Peterson DE, et al.Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline[J]. J Clin Oncol, 2019, 37(25): 2270-2290.
[4] Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws[J]. J Oral Maxillofac Surg, 2007, 65(3): 369-376.
[5] Ruggiero SL, Dodson TB, Assael LA, et al.American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update[J]. J Oral Maxillofac Surg, 2009, 67(5 Suppl): 2-12.
[6] Ruggiero SL, Dodson TB, Fantasia J, et al.American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update[J]. J Oral Maxillofac Surg, 2014, 72(10): 1938-1956.
[7] Ruggiero SL, Dodson TB, Aghaloo T, et al.American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws-2022 update[J]. J Oral Maxillofac Surg, 2022, 80(5):920-943.
[8] Marx RE.Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61(9): 1115-1117.
[9] Khan AA, Sandor GK, Dore E, et al.Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw[J]. J Rheumato, 2008, 35(7): 1391-1397.
[10] Raje N, Terpos E, Willenbacher W, et al.Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study[J]. Lancet Oncol, 2018, 19(3): 370-381.
[11] Bone HG, Wagman RB, Brandi ML, et al.10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension[J]. Lancet Diabetes Endocrinol, 2017, 5(7):513-523.
[12] 张志愿. 口腔颌面外科学[M].北京:人民卫生出版社,2020:130.
Zhang ZY.Oral and maxillofacial surgery[M]. Beijing: People's Medical Publishing House, 2020: 130.
[13] 潘剑, 刘济远. 药物相关性颌骨坏死的发病机制及其防治[J].华西口腔医学杂志, 2021, 39(3): 245-254.
Pan J, Liu JY.Mechanism,prevention,and treatment for medication-related osteonecrosis of the jaws[J]. West China Journal of Stomatology, 2021, 39(3): 245-254.
[14] Kalyan S, Quabius ES, Wiltfang J, et al.Can peripheral blood γδ T cells predict osteonecrosis of the jaw? an immunological perspective on the adverse drug effects of aminobisphosphonate therapy[J]. J Bone Miner Res, 2013, 28(4): 728-735.
[15] Silveira FM, Etges A, Correa MB, et al.Microscopic evaluation of the effect of oral microbiota on the development of bisphosphonate-related osteonecrosis of the jaws in rats[J]. J Oral Maxillofac Res, 2016, 7(4): e3.
[16] Jiang W, Rixiati Y, Zhao B, et al.Incidence, prevalence, and outcomes of systemic malignancy with bone metastases[J]. J Orthop Surg (Hong Kong), 2020, 28(2): 2309499020915989.
[17] Coleman RE, Croucher PI, Padhani AR, et al.Bone metastases[J]. Nat Rev Dis Primers, 2020, 6(1): 83-110.
[18] Fornetti J, Welm AL, Stewart SA.Understanding the bone in cancer metastasis[J]. J Bone Miner Res, 2018, 33(12):2099-2113.
[19] Huang JF, Shen J, Li X, et al.Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study[J]. Ann Transl Med, 2020, 8(7): 482-500.
[20] Pelaz A, Junquera L, Gallego L, et al.Epidemiology, pharmacology and clinical characterization of bisphosphonate-related osteonecrosis of the jaw. a retrospective study of 70 cases[J]. Acta Otorrinolaringol Esp, 2015, 66(3): 139-147.
[21] Sakaguchi O, Kokuryo S, Tsurushima H, et al.Lipopolysaccharide aggravates bisphosphonate-induced osteonecrosis in rats[J]. Int J Oral Maxillofac Surg, 2015, 44(4): 528-534.
[22] Boquete-Castro A, Gómez-Moreno G, Calvo-Guirado JL, et al.Denosumab and osteonecrosis of the jaw. a systematic analysis of events reported in clinical trials[J]. Clin Oral Implants Res, 2016, 27(3): 367-375.
[23] Hernandez RK, Quigley J, Pirolli M, et al.Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US[J]. Support Care Cancer, 2014, 22(10): 2697-2705.
[24] Coleman R, Woodward E, Brown J, et al.Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer[J]. Breast Cancer Res Treat, 2011, 127(2): 429-438.
[25] Lopez-Olivo MA, Shah NA, Pratt G, et al.Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis[J]. Support Care Cancer, 2012, 20(11): 2985-2998.
[26] Mauri D, Valachis A, Polyzos IP, et al.Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis[J]. Breast Cancer Res Treat, 2009, 116(3): 433-439.
[27] Beth-Tasdogan NH, Mayer B, Hussein H, et al. Interventions for managing medication-related osteonecrosis of the jaw[J]. Cochrane Database Syst Rev, 2022, 7(7): CD012432.
[28] Beth-Tasdogan NH, Mayer B, Hussein H, et al. Interventions for managing medication-related osteonecrosis of the jaw[J]. Cochrane Database Syst Rev, 2017, 10(10): CD012432.
[29] Grbic JT, Black DM, Lyles KW, et al.The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program[J]. J Am Dent Assoc, 2010, 141(11): 1365-1370.
[30] Feng Z, An J, He Y, et al.A comparative study of the clinical characteristics of patients with medication-related osteonecrosis of the jaw and osteoporosis or malignancy[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2022, 134(5):543-547.
[31] Ng TL, Tu MM, Ibrahim MFK, et al.Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review[J]. Support Care Cancer, 2021, 29(2): 925-943.
[32] Chen S, Ren H, He Y, et al.Recurrence-related factors of medication-related osteonecrosis of the jaw: a five-year experience[J]. J Oral Maxillofac Surg, 2021,79(12): 2472-2481.
[33] Saad F, Brown JE, Van Poznak C, et al: Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase Ⅲ trials in cancer patients with bone metastases[J]. Ann Oncol, 2012, 23(5): 1341-1347.
[34] McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: a systematic review[J]. Oral Dis, 2018, 24(4): 527-536.
[35] Tsao C, Darby I, Ebeling PR, et al.Oral health risk factors for bisphosphonate-associated jaw osteonecrosis[J]. J Oral Maxillofac Surg, 2013, 71(8): 1360-1366.
[36] Feng Z, An J, Zhang Y.Factors influencing severity of medication-related osteonecrosis of the jaw: a retrospective study[J]. J Oral Maxillofac Surg, 2021,79(8): 1683-1688.
[37] Hallmer F, Andersson G, Gotrick B, et al.Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2018, 126(6): 477-485.
[38] Aljohani S, Fliefel R, Ihbe J, et al.What is the effect of antiresorptive drugs (ARDs) on the development of medicationrelated osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a systematic review[J]. J Craniomaxillofac Surg, 2017, 45(9): 1493-1502.
[39] Watts NB, Grbic JT, Binkley N, et al.Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years[J]. J Clin Endocrinol Metab, 2019, 104(6): 2443-2452.
[40] Avishai G, Muchnik D, Masri D, et al.Minimizing MRONJ after tooth extraction in cancer patients receiving bone-modifying agents[J]. J Clin Med, 2022, 11(7): 1807-1816.
[41] Hasegawa T, Hayashida S, Kondo E, et al.Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study[J]. Osteoporos Int, 2019, 30(1): 231-239.
[42] Kyrgidis A, Vahtsevanos K, Koloutsos G, et al.Bisphosphonaterelated osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients[J]. J Clin Oncol, 2008, 26(28): 4634-4638.
[43] Vahtsevanos K, Kyrgidis A, Verrou E, et al.Longitudinal cohort study of risk factors in cancer patients of bisphosphonaterelated osteonecrosis of the jaw[J]. J Clin Oncol, 2009, 27(32):5356-5362.
[44] Yamazaki T, Yamori M, Ishizaki T, et al.Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study[J]. Int J Oral Maxillofac Surg, 2012, 41(11): 1397-1403.
[45] Qi WX, Tang LN, He AN, et al.Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials[J]. Int J Clin Oncol, 2014, 19(2): 403-410.
[46] 周桂龙, 田磊, 邵小夕, 等. 关于药物相关性颌骨坏死的研究进展[J].现代口腔医学杂志, 2019, 33(4): 237-242.
Zhou GL, Tian L, Shao XX, et al.Research progress on drug-related jaw necrosis[J]. Journal of Modern Stomatology, 2019, 33(4): 237-242.
[47] Gupta S, Gupta H, Mandhyan D, et al.Bisphosphonate related osteonecrosis of the jaw[J]. Natl J Maxillofac Surg, 2013, 4(2): 151-158.
[48] Arce K, Assael LA, Weissman JL, et al.Imaging findings in bisphosphonate- related osteonecrosis of jaws[J]. J Oral Maxillofac Surg, 2009, 67(5 Suppl): S75-84.
[49] 郭玉兴, 张建运, 王佃灿, 等. 药物相关颌骨骨坏死的病理特点及临床治疗策略[J]. 北京大学学报(医学版), 2022, 54(6): 1190-1195.
Guo YX, Zhang JY, Wang DC, et al.Analysis of pathological characteristics of medication-related osteonecrosis of the jaw and discussion of clinical treatment strategies based on the pathological analysis results[J]. Journal of Peking University: Health Sciences, 2022, 54(6): 1190-1195.
[50] 何海波, 龚淼, 张志闻. 颌骨转移癌临床分析[J]. 中国继续医学教育, 2016, 8(34): 104-105.
He HB, Gong M, Zhang ZW.Clinical analysis of metastatic carcinoma of the jaws[J]. China Continuing Medical Education, 2016, 8(34): 104-105.
[51] Owosho A, Xu B, Kadempour A, et al.Metastatic solid tumors to the jaw and oral soft tissue: a retrospective clinical analysis of 44 patients from a single institution[J]. J Craniomaxillofac Surg, 2016, 44(8): 1047-1053.
[52] Kawaguchi M, Kato H, Nakano M, et al.Clinical features of bone metastasis with extraosseous soft-tissue mass in prostate cancer patients[J]. BJR Open, 2019, 1(1): 20180042.
[53] Zhu Y, Liang J, Wang F, et al.Bacterial spectrum analysis and antimicrobial susceptibility study of osteoradionecrosis of the jaw in Southern China[J]. Oral Dis, 2022, 28(7): 2015-2025.
[54] Li Q, Pu Y, Lu H, et al.Porphyromonas, Treponema, and Mogibacterium promote IL8/IFN/TNF-based pro-inflammation in patients with medication related osteonecrosis of the jaw[J]. J Oral Microbiol, 2021, 13(1): 1851112.
[55] Kim KM, Rhee Y, Kwon YD, et al.Medication related osteonecrosis of the jaw: 2015 position statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons[J]. J Bone Metab, 2015, 22(4): 151-165.
[56] Yoneda T, Hagino H, Sugimoto T, et al.Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw[J]. J Bone Miner Metab, 2017, 35(1): 6-19.
[57] Chalem M, Medina A, Sarmiento AK, et al.Therapeutic approach and management algorithms in medication-related osteonecrosis of the jaw (MONJ): recommendations of a multidisciplinary group of experts[J]. Arch Osteoporos, 2020, 15(1): 101.
[58] 刘忠龙, 姜钧健, 李晓光, 等. 一种新的药物性颌骨坏死临床分期及治疗策略[J]. 中国口腔颌面外科杂志, 2020, 18(6): 501-507.
Liu ZL, Jiang JJ, Li XG, et al.A novel staging system and corresponding therapeutic strategies for medication-related osteonecrosis of the jaw[J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(6): 501-507.
[59] Ji X, Pushalkar S, Li Y, et al.Antibiotic effects on bacterial profile in osteonecrosis of the jaw[J]. Oral Dis, 2012, 18(1): 85-95.
[60] Vescovi P, Nammour S. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) therapy: a critical review[J]. Minerva Stomatol, 2010, 59(4): 181-203, 204-113.
[61] Hoefert S, Eufinger H.Relevance of a prolonged preoperative antibiotic regime in the treatment of bisphosphonate-related osteonecrosis of the jaw[J]. J Oral Maxillofac Surg, 2011, 69(2): 362-380.
[62] Damm DD, Jones DM.Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays[J]. Gen Dent, 2013, 61(5): 33-38.
[63] Allen BW, Demchenko IT, Piantadosi CA.Two faces of nitric oxide: implications for cellular mechanisms of oxygen toxicity[J]. J Appl Physiol(1985), 2009, 106(2): 662-667.
[64] Piantadosi CA, Tatro LG.Regional H2O2 concentration in rat brain after hyperoxic convulsions[J]. J Appl Physiol(1985), 1990, 69(5): 1761-1766.
[65] Demchenko IT, Boso AE, O'Neill TJ, et al. Nitric oxide and cerebral blood flow responses to hyperbaric oxygen[J]. J Appl Physiol(1985), 2000, 88(4): 1381-1389.
[66] Demchenko IT, Boso AE, Whorton AR, et al.Nitric oxide production is enhanced in rat brain before oxygen-induced convulsions[J]. Brain Res, 2001, 917(2): 253-261.
[67] Freiberger JJ.Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws[J]. J Oral and Maxil Surg, 2009, 67(5 Suppl): 96-106.
[68] Freiberger JJ, Padilla-Burgos R, McGraw T, et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics[J]. J Oral Maxil Surg, 2012, 70(7): 1573-1583.
[69] Epstein MS, Wicknick FW, Epstein JB, et al.Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. an initial case series[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2010, 110(5): 593-596.
[70] Magremanne M, Reychler H.Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid induced osteoporosis[J]. J Oral Maxil Surg, 2014, 72(2): 334-337.
[71] Chen T, Wang Y, Hao Z, et al.Parathyroid hormone and its related peptides in bone metabolism[J]. Biochem Pharmacol, 2021, 192: 114669.
[72] Cheung A, Seeman E.Teriparatide therapy for alendronate-associated osteonecrosis of the jaw[J]. New Engl J Med, 2010, 363(25): 2473-2474.
[73] Dayisoylu EH, Senel FÇ, Ungör C, et al.The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study[J]. Int J Oral Maxillofac Surg, 2013, 42(11): 1475-1480.
[74] Kim KM, Park W, Oh SY, et al.Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw[J]. Osteoporosis Int, 2014, 25(5): 1625-1632.
[75] Kakehashi H, Ando T, Minamizato T, et al.Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings[J]. Int Oral Maxillofac Surg, 2015, 44(12): 1558-1564.
[76] Sim IW, Borromeo GL, Tsao C, et al.Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial[J]. J Clin Oncol, 2020, 38(26): 2971-2980.
[77] Mozzati M, Gallesio G, Arata V, et al.Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases[J]. Oral oncol, 2012, 48(5): 469-474.
[78] Kim JW, Kim SJ, Kim MR.Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study[J]. Br J Oral Maxillofac Surg, 2014, 52(9): 854-859.
[79] Dincǎ O, Zurac S, Stǎniceanu F, et al.Clinical and histopathological studies using fibrin-rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw[J]. Rom J Morphol Embryol, 2014, 55(3): 961-964.
[80] Nørholt SE, Hartlev J.Surgical treatment of osteonecrosis of the jaw with the use of platelet-rich fibrin: a prospective study of 15 patients[J]. Int J Oral Maxillofac Surg, 2016, 45(10): 1256-1260.
[81] Park JH, Kim JW, Kim SJ.Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw?[J]. J Oral Maxillofac Surg, 2017, 75(6):1176-1184.
[82] Baba A, Goto TK, Ojiri H, et al.CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medicationrelated osteonecrosis of the jaw[J]. Dentomaxillofac Radiol, 2018, 47(4): 20170323.
[83] Melville JC, Tursun R, Shum JW, et al.A technique for the treatment of oral-antral fistulas resulting from medication-related osteonecrosis of the maxilla: the combined buccal fat pad flap and radical sinusotomy[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2016, 122(3): 287-291.
[84] Aljohani S, Troeltzsch M, Hafner S, et al.Surgical treatment of medication-related osteonecrosis of the upper jaw: case series[J]. Oral Dis, 2019, 25(2): 497-507.
[85] 田美,王丹妮,罗舒艳,等. 上颌骨药物相关性颌骨坏死的手术治疗效果初探[J]. 中华口腔医学杂志, 2021, 56(5): 447-451.
Tian M, Wang DN, Luo SY, et al.Effect of the surgical treatment of maxillary medication-related osteonecrosis of the jaw[J]. Chinese Journal of Stomatology, 2021, 56(5): 447-451.
[86] 安金刚, 吕晓鸣, 贾宽宽. 下颌下腺转位在下颌骨3期药物相关性颌骨坏死手术中的应用[J]. 中华口腔学杂志, 2021, 56(5): 441-446.
An JG, Lyu XM, Jia KK.Application of the submandibular gland for management of stage 3 medication-related osteonecrosis of the mandible[J]. Chinese Journal of Stomatology, 2021,56(5): 441-446.
[87] Carlson ER, Basile JD.The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws[J]. J Oral Maxillofac Surg, 2009, 67(5 Suppl): 85-95.
[88] Klingelhöffer C, Klingelhöffer M, Müller S, et al.Can dental panoramic radiographic findings serve as indicators for the development of medication-related osteonecrosis of the jaw?[J]. Dentomaxillofac Radiol, 2016, 45(5): 20160065.
[89] 陈珩, 何悦. MASCC/ISOO/ASCO药物相关性颌骨坏死临床实践指南解读[J].中华口腔医学杂志, 2022, 57(2): 128-135.
Chen H, He Y.Interpretation of medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline[J]. Chinese Journal of Stomatology, 2022, 57(2): 128-135.
[90] Bacci C, Cerrato A, Bardhi E, et al.A retrospective study on the incidence of medication-related osteonecrosis of the jaws (MRONJ) associated with different preventive dental care modalities[J]. Support Care Cancer, 2022, 30(2): 1723-1729.
[91] Mauceri R, Coniglio R, Abbinante A, et al.The preventive care of medication-related osteonecrosis of the jaw(MRONJ): a position paper by Italian experts for dental hygienists[J]. Support Care Cancer, 2022, 30(8): 6429-6440.
[92] 郭玉兴, 赵宁, 王佃灿, 等. 以带蒂颊脂垫为基础的双层软组织封闭技术修复药物相关颌骨坏死手术后上颌骨缺损的临床应用[J]. 华西口腔医学杂志, 2022, 40(1): 61-67.
Guo YX, Zhao N, Wang DC, et al.Clinical application of double-layer soft tissue closure technology based on pedicled buccal fat pad in repairing maxillary defects after medication-related osteonecrosis of jaw surgery[J]. West China Journal of Stomatology, 2022, 40(1): 61-67.
[93] Di Fede O, Panzarella V, Mauceri R, et al.The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention[J]. Biomed Res Int, 2018: 2684924.
[94] Poxleitner P, Engelhardt M, Schmelzeisen R, et al.The prevention of medication-related osteonecrosis of the jaw[J]. Dtsch Arztebl Int, 2017, 114(5): 63-69.
[95] Zirk M, Wenzel C, Buller J, et al.Microbial diversity in infections of patients with medication-related osteonecrosis of the jaw[J]. Clin Oral Investig, 2019, 23(5): 2143-2151.

Expert consensus on diagnosis and clinical management of medication-related osteonecrosis of the jaw

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	LIU Bing, HE Yue, PENG Xin, SUN Chang-fu, HAN Zheng-xue, WU Yu-nong, PENG Li-wei, ZHAO Yi, TAO Qian, HAN Xin-guang, LI Jin-song, SU Tong, LI Bo, ZHANG Lei, HU Yan-ping, CHEN Chuan-jun, LI Yi, LI Tie-jun, ZHAO Yi-fang. Chinese Expert consensus on the diagnosis, treatment of odontogenic keratocyst [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(3): 209-218.
[2]	WANG Yu-xin, WANG Zhi-yong, WANG Yong-gong, WANG Hui-ming, WANG Li-zhen, TIAN Hao, YE Jin-hai, FU Kun, RUAN Min, SUN Chang-fu, SUN Guo-wen, LIU Fa-yu, XU Bi-yun, HOU Jun, LIU Bing, LIU Liang, CHEN Yong-feng, CHEN Zhan-wei, XIAO Can, LI Si-yi, LI Zhi-yong, LI Yong, LI Nan, ZHANG Chen-ping, ZHANG Dong-sheng, ZHANG Sheng, ZHANG Kai, YANG Xi, HE Wei, SU Tong, JI Tong, LIN Li-song, LUO Rui-hua, ZHAO Zhi-li, HU Qin-gang, TANG Zhan-gui, XU Wei-jia, HUANG Zhi-quan, HUANG Xiao-feng, LIANG Yu-jie, HAN Zheng-xue, HAN Wei, JIANG Can-hua, YU Jian-jun, CAI Zhi-gang, LIAO Gui-qing, LIAO Sheng-kai, CAI Hui-ming, WEI Jian-hua. Chinese expert consensus statement on the application of of indocyanine green(ICG) fluorescence imaging in the treatment of oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(1): 1-6.
[3]	GUO Wei, REN Guo-xin, SUN Mo-yi, KONG Yun-yi, WANG Li-zhen, BU Rong-fa, RAN Wei, TANG Zhan-gui, LI Long-jiang, MENG Jian, SUN Zhi-jun, SHANG Wei, LV Jiong, WU He-ming, ZHANG Chen-ping, HE Yue, MA Xu-hui, SONG Hao, JU Hou-yu, ZHENG Jia-wei, GONG Zhong-cheng, YANG Kai, ZHANG Jie, WU Yun-teng. Expert consensus on clinical diagnosis and treatment for Chinese oral mucosal melanoma [J]. China Journal of Oral and Maxillofacial Surgery, 2021, 19(6): 481-488.
[4]	CHEN Chuan-jun, CHEN Wei-liang, SUN Chang-fu, HE Yue, JIANG Can-hua, PENG Xin, SHANG Zheng-jun, HAN Zheng-xue, LI Jin-song, HOU Jin-song, LIN Li-song, HAN Xin-guang, WEI Jian-hua, WANG Zhi-yong, WU Yu-nong, ZHENG Jia-wei, LI Long-jiang, WANG Hui-ming, LI Zu-bing, GUO Chuan-bin, YANG Chi, SHI Bing, ZHANG Zhi-yuan. Expert consensus on application of submental island flap in oromaxillofacial head and neck defect reconstruction [J]. China Journal of Oral and Maxillofacial Surgery, 2021, 19(5): 385-391.
[5]	PAN Meng-qi, LI Zhi-yong, ZHAO Wen-quan. Interpretation of ASCO clinical practice guideline:management of the neck in squamous cell carcinoma of the oral cavity and oropharynx issued in 2019 [J]. China Journal of Oral and Maxillofacial Surgery, 2021, 19(2): 177-180.
[6]	LIU Zhong-long, JIANG Jun-jian, LI Xiao-guang, ZHU Feng-shuo, TANG Xiao, ZHU Ling, HE Yue. A novel staging system and corresponding therapeutic strategies for medication-related osteonecrosis of the jaw [J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(6): 501-507.
[7]	HE Yue, JIANG Can-hua, HOU Jin-song, WANG Hui-ming, PENG Xin, LIU Bing, LI Jin-song, ZHENG Lei, XU Zhong-fei, WU Yu-nong, HU Jing-zhou, QIN Xing-jun, AI Song-tao, ZHOU Hui-hong, LI Chun-jie, ZHANG Shi-zhou, WANG Jun, LI Xiao-guang, LIU Zhong-long, ZHU Feng-shuo. Expert consensus statement on application of perforator flap in oromaxillofacial head and neck defect reconstruction [J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(5): 385-389.
[8]	Professional Committee of Teeth and Alveolar Surgery, Chinese Stomatological Association. Chinese expert consensus on standardized operation process of autotransplantation of teeth [J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(5): 390-394.
[9]	JIANG Jun-jian, HE Yue. Research progress on treatment of medication-related osteonecrosis of the jaw [J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(5): 474-477.
[10]	JU Hou-yu, ZHENG Jia-wei, SUN Mo-yi, TANG Zhan-gui, YANG Dao-ke, RAN Wei, BU Rong-fa, SHANG Wei, MENG Jian, WU He-ming, XI Qing, YANG Kai, WANG Jun, WU Yun-teng, REN Guo-xin, GUO Wei. Chinese expert consensus on ultrasound hyperthermia for oral and maxillofacial head and neck squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(3): 193-198.
[11]	TANG Zhan-gui, BU Rong-fa, GUO Wei, SUN Mo-yi, ZHENG Jia-wei, PENG Xin, ZHANG Hui, DUAN Xiao-hong, JIANG Hong, WANG Miao, ZHANG Tie-jun, YANG Xu-dong, YANG Kai, YU Jian-jun, LUO Zhi-yong, XIE Yong-qiu, HU Yan-jia, WANG Bai-sheng. Chinese expert consensus on diagnosis and clinical management of malignant hyperthermia in oral medicine [J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(1): 1-9.
[12]	SHANG Wei, ZHENG Jia-wei. Interpretation of updated NCCN guidelines for diagnosis and treatment of oral and oropharyngeal cancer issued in 2019 [J]. China Journal of Oral and Maxillofacial Surgery, 2019, 17(6): 481-485.
[13]	JIANG Can-hua, JIAN Xin-chun, ZHANG Zhi-yuan, ZHENG Jia-wei, SHI Bing, LIU Yan-pu, HE Yue, PENG Xin, SHANG Zheng-jun, HAN Xin-guang, LIU Wei-dong, MO Yang, GUO Feng, CHENG Zhi-gang, CHEN Chuan-jun, GONG Zhong-cheng, JIN Wu-long, ZHANG Shi-zhou, YUAN Rong-tao, YAN Feng-guo, LI Peng-cheng, ZHANG Sheng, GAO Xing, CHEN Jie. Chinese expert consensus on oral and maxillofacial ambulatory surgery [J]. China Journal of Oral and Maxillofacial Surgery, 2019, 17(5): 385-390.
[14]	LIU Jian-hua, ZHANG Zhi-yuan, SHI Bing, GUO Chuan-bin, SUN Jian, WANG Hui-ming, SUN Chang-fu, ZHENG Qian. Treatment protocols for lip defects based on local flap reconstruction: Chinese expert consensus [J]. China Journal of Oral and Maxillofacial Surgery, 2019, 17(5): 391-396.
[15]	LI Ke-lei, YAO Wei, QIN Zhong-ping, LI Kai, ZHENG Jia-wei, FAN Xin-dong, MA Lin, ZHOU De-kai, LIU Xue-jian, WEI Li, LI Li, TAI Mao-zhong, WANG Jin-hu, JI Yi, ZHOU Ling, HUANG Hai-jin, GAO Xiao-yun, HUANG Zhi-jian, GU Song, YANG He-ying. Chinese expert consensus on diagnosis and treatment of Kasabach-Merritt phenomenon [J]. China Journal of Oral and Maxillofacial Surgery, 2019, 17(2): 97-105.